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ABSTRACT  
 
Background: Considering that most of semantic dementia (SD) and frontotemporal dementia 
(FTD) patients show no postmortem Alzheimer’s disease (AD) pathology, cerebrospinal fluid 
(CSF) biomarkers may be of value for distinguishing these patients from those with AD. 
Additionally, biomarkers may be useful for identifying patients with atypical phenotypic 
presentations of AD, such as posterior cortical atrophy (PCA) and primary progressive non-
fluent or logopenic aphasia (PNFLA).  
Methods: We investigated CSF biomarkers (beta-amyloid 1-42 (Aβ42), total tau (T-tau), and 
phosphorylated tau [P-tau]) in 164 patients with AD (n=60), PCA (n=15), behavioral variant 
FTD (n=27), SD (n=19), (PNFLA) (n=26) and functional cognitive disorders (FCD, n=17). 
We then examined the diagnostic value of these CSF biomarkers in distinguishing the patients 
from those with AD.  
Results:  The P-Tau/Aβ42 ratio was found to be the best biomarker for discriminating AD 
from FTD and SD, with a sensitivity of 91.7% and 98.3%, respectively, and a specificity of 
92.6% and 84.2%, respectively. As expected, biomarkers were less effective in differentiating 
AD from PNFLA and PCA, as significant proportions of PCA and PNFLA patients (60% 
and 61.5%, respectively) had concurrent alterations of both T-tau/Aβ42 and P-Tau/Aβ42 ratios. 
None of the FCD patients had a typical AD CSF profile or abnormal T-tau/Aβ42 or P-
Tau/Aβ42 ratios.  
Conclusion: The P-Tau/Aβ42 ratio is a useful tool to discriminate AD from both FTD and SD, 
which are known to involve pathological processes distinct from AD. Biomarkers could be 
useful for identifying patients with an atypical AD phenotype that includes PNFLA and PCA.  
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INTRODUCTION 
With the prospect of disease-modifying drugs that will target the physiopathological 
process of Alzheimer’s disease (AD), it is crucial to improve the efficacy of the differential 
diagnosis between AD and other cortical dementia. The determination of cerebrospinal fluid 
(CSF) biomarker profiles of cortical dementias may ameliorate the distinction between AD 
and newly characterized non-AD dementias, such as frontotemporal dementia (FTD) and 
semantic dementia (SD). In addition, it may identify potential patients with atypical 
phenotypic presentation of AD, such as posterior cortical atrophy (PCA) and primary 
progressive aphasia (PPA), who may be candidates for emerging therapies. 
The CSF biomarkers total tau (T-tau), phosphorylated tau (P-tau) and beta-amyloid 
peptide 1-42 (Aβ42) can distinguish controls from AD subjects [1, 2], even in early stages of 
the disease [3-8]. The accuracy of CSF biomarkers in the differential diagnosis between AD 
and other cortical dementias, however, is not well understood. Previous studies have primarily 
focused on the interest of biomarkers to discriminate AD from frontal variants of 
frontotemporal lobar degenerations (FTLD), which are defined by behavioral changes. These 
studies have found that CSF biomarkers are useful in discriminating AD from FTD [9-17], 
and one study [11] demonstrated the high sensitivity and specificity of biomarkers in 
distinguishing AD from proven FTD (confirmation via autopsy and genetics). 
Besides these data, some important questions remain unresolved. First, the ability of 
CSF biomarkers to distinguish AD from non-behavioral variants of FTLDs, such as SD, 
remains to be studied. The diagnosis of SD can be difficult and is a common cause of the 
misdiagnosis of AD [18]. While neuropathological studies have reported a lack of AD lesions 
in most SD patients [18-21], one study (which included a small sample of patients) reported 
that CSF biomarkers in SD subjects showed a similar CSF profile to that of AD patients [14], 
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showing an unexpected low power of biomarkers to discriminate between these two distinct 
pathologies.  
The second unsolved question is the ability of CSF biomarkers to identify AD pathology 
in atypical focal cortical presentations of AD, such as PCA and logopenic PPA [18, 19, 22]. 
Different from AD, PCA and logopenic PPA are characterized by specific clinical 
presentations (e.g., visual-spatial difficulties in PCA), with relative respect to episodic 
memory and focal atrophy. The most frequent underlying pathology found in autopsy studies, 
however, is AD [18]. Thus, these conditions have been coined focal cortical presentations of 
AD [18]. Biomarkers may be able to identify the biological mechanisms of PCA and PPA and 
may also be useful for selecting patients who would benefit from new disease-modifying 
therapies.  
The main objective of this study was to analyze the usefulness of CSF biomarkers for 
discriminating AD from FTD, SD, PCA and primary progressive non-fluent or logopenic 
aphasia (PNFLA). We analyzed individual data to identify how CSF biomarkers can be 
included in the differential diagnosis of AD in clinical practice.  
 
METHODS 
The study included 164 patients hospitalized between May, 2007, and July, 2009, at the 
Center of Cognitive and Behavioral Diseases, Pitié-Salpêtrière Hospital, Paris, France (n=160 
patients) or at the University Hospital of Rennes (France) (n=4 patients). 
All patients were evaluated by neurologists experienced in the care of patients with 
neurodegenerative diseases. All patients underwent a neuropsychological examination that 
included the Mini Mental State Exam [23], free and cued selective reminding test (FCSRT) 
[24] for verbal episodic memory, Frontal Assessment Battery [25] for executive functions, 
digit spans for working memory, Verbal Fluency (letter S and category: fruit in 2 minutes) 
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[26], gestual praxis and visuoconstructive function by copying the Rey figure or MMSE 
pentagons. When dementia other than that observed in AD was clinically suspected, an 
additional specific neuropsychological battery was administered to increase the specificity of 
the clinical diagnosis using tests to assess orbitofrontal function for FTD, semantic memory 
for SD, and Balint’s syndrome and Gerstman syndrome for PCA.  
All patients underwent standardized serum tests (for B12, thyroid functioning, 
sedimentation rate, and so on) to investigate other causes of non-neurodegenerative dementia 
in younger patients. All subjects underwent structural magnetic resonance imaging (MRI) or 
computed tomography (CT) when MRI was not possible. Brain perfusion (99m)Tc-ECD 
SPECT was proposed for most of the patients (n= 131/164), especially when a non-AD 
dementia diagnosis was suspected. 
Patients were excluded from the study if they presented any of the following: 1) 
systemic illnesses that could interfere with cognitive functioning; 2) extrapyramidal signs or 
neurological history suggestive of Parkinson’s disease with dementia, progressive 
supranuclear palsy, corticobasal degeneration or dementia with Lewy bodies; 3) vascular 
lesions on MRI or neurological history suggestive of vascular dementia; or 4) motor-neuron 
disease. 
Patients were divided into the following six distinct diagnostic groups: (1) probable AD 
according to NINCDS-ADRDA criteria [27]; (2) behavioral variant of FTLD according to the 
latest revised criteria [28, 29]; (3) SD, defined as a primary progressive aphasia and 
characterized by fluent speech, marked anomia, impaired word comprehension, deficits in 
non-verbal semantic association tasks and possible prosopagnosia [28, 30, 31]; (4) PNFLA, 
characterized by the presence of predominant effortful speech output with word finding 
difficulty, possible phonological and/or syntactic errors, relative sparing of single-word 
comprehension and possible deficits in sentence repetition [20, 32, 33]; 5) PCA, defined by 
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initial presentation of progressive visual or visuospatial impairment in the absence of 
ophthalmologic impairment with evidence of complex visual and/or visuospatial disorder on 
examination and a relatively preserved episodic memory [34, 35]; and 6) functional cognitive 
disorders (FCD), defined as a psychiatric diagnosis, such as depression, bipolar disorders or 
generalized anxiety disorders.  
Most of patients were on symptomatic treatment (mainly anticholinesterasic medications 
and/or serotonin-specific reuptake inhibitor). 
To improve diagnostic accuracy, all patients were clinically followed for at least 18 
months (at least 6 months before lumbar puncture and at least 12 months after lumbar 
puncture). The probable clinical diagnosis was established according to the above clinical 
criteria using a consensus mechanism blind to CSF biomarkers values. The clinical diagnosis 
was then coupled with laboratory data for CSF biomarkers to establish the sensitivity and 
specificity for each CSF biomarker to distinguish AD patients from other groups of patients. 
 
Sample collection and biochemical measurements 
CSF samples obtained by lumbar puncture were centrifuged for 10 minutes at 1500 rpm 
at 4°C to remove cells, aliquoted to 0.4 mL samples in polypropylene tubes and stored at 
−80°C until analysis. CSF biomarker levels of T-tau, P-Tau at threonine 181 and Aβ42 were 
measured in duplicate using the double sandwich ELISA method (Innogenetics) according to 
the manufacturer’s instructions. We also calculated derived ratios from single biomarkers, 
including T-tau/Aβ42 and P-Tau/Aβ42.   
Analyses for all patients, except for four, were performed in the Metabolic Biochemistry 
Department at the Pitié-Salpêtrière Hospital; analyses for the remaining four patients were 
performed at the Biological Neurochemistry laboratory at the University Hospital of Rennes. 
All operators were blind to clinical information.  
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All biological and clinical data were generated during a routine clinical work-up and 
were retrospectively extracted for the purpose of this study. Therefore, according to French 
legislation, explicit informed consent was waived. However, regulations concerning 
electronic filing were followed, and patients and their relatives were informed that individual 
data might be used in retrospective clinical research studies.  
 
Statistical analysis 
All statistical analyses were performed using Statview 4.0 (SAS Institute Inc., Version 
5.0), MedCalc Software and STATISTICA 5.5A (© StatSoft, Tulsa, Oklahoma, USA). 
Descriptive statistics were used to characterize each clinical group. 
The samples were checked for normality by the Shapiro-Wilk test, which revealed that 
CSF biomarkers did not follow a normal distribution. The Mann-Whitney U-test was then 
employed to assess differences in demographics and biological data between the AD group 
and each of the other five clinical groups. The chi-square test was used to compare gender 
ratios. An alpha (significance) level of 0.05 was chosen.  
Receiver operating characteristics (ROC) curve analyses were performed to evaluate the 
discriminating power of the different biomarkers and clinical diagnosis. The area under the 
curve (AUC) was used as a measure of the overall performance of each ROC curve (with a 
95% confidence interval). Moreover, we assessed whether the AUC values were significantly 
different using a nonparametric method for correlated samples (Delong’s method). Finally, 
optimal cutoff points of biomarkers were calculated by selecting the point on the ROC curve 
that maximized both sensitivity and specificity.  
The Spearman coefficient test was used to assess correlations between CSF variables, 
age, MMSE and disease duration. Bonferroni correction for multiple comparisons was 
applied.  
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Because differences between the groups in CSF collection, CSF storage and center of 
recruitment were seen as potential sources of bias, we conducted further analyses that resulted 
in exclusion of the four patients who came from the Hospital of Rennes, all of whom were in 
the SD group. However, the results were not significantly modified after excluding these 
patients.  
 
RESULTS 
Patient characteristics and mean CSF biomarker levels  
Demographic data, clinical data and CSF biomarker levels for each group of patients are 
shown in Table 1 (and table 4, as supplementary material on-line). There were no significant 
differences in age or mean disease duration between the AD group and each of the non-AD 
dementia groups (FTD, SD, PNFLA and PCA). Gender distribution was similar between the 
AD group and each of the non-AD dementia groups, except for PCA and PNFLA groups. No 
differences in the MMSE score were found between the AD group and non-AD dementia 
groups, except for SD patients who had slightly higher MMSE score than AD patients. 
Patients with FCD were younger than the AD patients and had a higher MMSE score. Gender 
distribution in FCD group was similar to the AD group.  
The CSF Aβ42 levels were significantly lower in the AD group compared with the FCD 
and SD groups, and the FTD levels were between the AD and SD group levels. No 
differences in CSF Aβ42 levels were found among the AD, PCA and PNFLA groups 
(AD=PCA= PNFLA <FTD<FCD).  
The CSF T-tau and P-tau levels were significantly increased in the AD group compared 
with the FCD, FTD, SD and PNFLA groups (AD>PFNLA>SD=FTD=FCD, for both 
biomarkers). This was especially true with the FCD, FTD and SD groups (p < 0.0001 for both 
markers). These differences, however, were less significant when compared with the PNFLA 
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patients (p < 0.01 for Tau and p < 0.05 for P-Tau). There were no significant differences 
between the AD and PCA groups in T-tau levels. 
The T-tau/Aβ42 and P-Tau/Aβ42 ratios were significantly higher in AD patients relative 
to FCD, FTD or SD patients (p < 0.0001 for both ratios). In addition, T-tau/Aβ42 and P-
Tau/Aβ42 ratios were reduced in PNFLA and PCA patients relative to AD patients (p < 0.01 
and p < 0.05, respectively; AD>PNFLA=PCA>FTD=SD>FCD).  
Aβ42 levels and the two ratios differed significantly between the FCD group and the 
FTD group. However, there were no differences in the CSF biomarker levels between the 
FTD and SD groups. All biomarker measures were significantly different in the PNFLA and 
PCA groups when compared with the FTD or SD groups.  
No correlation was found between Aβ42 and T-tau or P-Tau levels for the entire 
population or within each group. A linear regression analysis between CSF T-tau and P-Tau 
levels showed a significant correlation for all groups studied (data not shown).  
We also analyzed statistical correlation (Spearman test, with Bonferroni correction) 
between different CSF biomarkers and clinical data (age, disease duration or MMSE). The 
different CSF biomarkers and ratios (Aβ42, T-tau, P-Tau, T-tau/Aβ42 and P-Tau/Aβ42) showed 
no significant correlations with age, gender, disease duration or MMSE for the entire 
population or within each group (the corrected p did reach significance level for none of the 
correlations). 
 
Determination of the sensitivity, specificity and optimal biomarker cutoff for differential 
AD diagnosis 
A pairwise comparison of the area under the ROC curves revealed that T-tau/Aβ42 and 
P-tau/Aβ42 were better than each separated CSF biomarkers in discriminating AD patients 
from FCD, FTD, SD, PNFLA and PCA (see Figure 1). Based on the AUC, sensitivity and 
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specificity, the P-tau/Aβ42 ratio discriminated AD from FCD and others cortical dementias 
better than Aβ42, T-tau, P-tau and T-tau/Aβ42. 
Table 2 shows the sensitivity, specificity, AUC and optimal cutoffs determined by ROC 
analysis for discriminating the AD group from each clinical group.  
The T-tau/Aβ42 and the P-tau /Aβ42 ratios better differentiated AD patients from SD or 
FTD patients than the individual CSF markers alone. The T-tau/Aβ42 ratio discriminated AD 
from SD or FTD patients with a 95% sensitivity (for both groups), and an 84.2% and 85.2% 
specificity, respectively. Similarly, the sensitivity for the P-tau/Aβ42 ratio for discriminating 
AD from FTD or SD was 91.7% and 98.3%, respectively, whereas the specificity was 92.6% 
and 84.2%, respectively (see Table 2). In contrast, CSF biomarkers and their ratios were less 
effective at discriminating AD from PNFLA and PCA patients.  
Because we wanted to determine the optimal cutoff for a differential diagnosis of AD, 
we grouped SD and FTD patients into an FTLD group. ROC curve analysis showed that 
sensitivity and specificity of P-tau /Aβ42 ratio remained high (91% and 89%, respectively). 
When the FCD and FTLD groups were pooled, we found a similar or higher sensitivity and 
specificity, except for the T-tau levels, as when the groups were considered alone. By 
comparing the FTLD group and FTLD pooled with FCD, the significant threshold for Aβ42, 
P-tau, T-tau/Aβ42 and P-tau/Aβ42 did not change. The T-tau cut-off was higher in the FTLD 
group than the FTLD group pooled with the FCD group. 
 
Individual biomarker profiles by diagnosis group  
To identify how CSF biomarkers can be included in the differential diagnosis of AD in 
clinical practice, we analyzed the percentages of patients by groups with altered levels of CSF 
biomarkers (Table 3). We chose the optimal cut-off determined by ROC analyses for 
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discriminating FTLD and AD groups because of the known differences in underlying 
histopathological characteristics between the diseases.  
As expected, 90% of AD patients had both abnormal T-tau/Aβ42 and P-tau/Aβ42, 
whereas only one (3.7%) FTD patient and three (15.8%) SD patients had abnormal scores for 
both ratios. No FCD patients had abnormal scores for either CSF ratio. In contrast, at least 
60% of PCA and PNFLA patients had both abnormal T-tau/Aβ42 and P-tau/Aβ42 ratios.  
Figure 2 shows a scatterplot of CSF P-tau/Aβ42 ratio in patients according to clinical 
diagnosis. A distinct distribution was observed between AD and FTD, SD and FCD patient 
data. By contrast, the distribution of P-tau/Aβ42 ratio in AD patient data overlapped with 
PNFLA and PCA patient data.  
 
DISCUSSION 
We investigated the ability of CSF biomarkers to distinguish AD from other forms of 
neurodegenerative cortical dementia. The CSF biomarker levels in AD patients found here 
were similar to those typically observed in AD patients [1, 5]. In analyzing the ability of CSF 
biomarkers to differentiate AD from non-AD dementias or FCD, two main findings emerged. 
First, the combined CSF biomarker profiles measured by the T-Tau/Aβ42 or P-Tau/Aβ42 
ratios were able to differentiate AD from FTD, SD and FCD with very high sensitivity and 
specificity. These data indicate that FTD, SD and FCD were distinct from AD in their 
underlying biological causes. Conversely, CSF biomarkers were not able to differentiate AD 
from PCA and PNFLA with the same high accuracy, suggesting heterogeneity within the 
PCA and PNFLA patients and a possibility of AD pathology in some cases. 
In agreement with previous studies [10, 11, 13-15], we found higher mean levels of CSF 
Tau and P-Tau and lower mean levels of CSF Aβ42 in FTD patients, when compared to AD 
subjects. The P-Tau/Aβ42 ratio appears to be the best biomarker profile for discriminating 
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AD from FTD, with a sensitivity of 91.7%, a specificity of 92.6% and very few false-positives 
(7%). This finding is consistent with a previous study that reported a sensitivity of 77% and 
specificity of 81% for the P-Tau/Aβ42 ratio in distinguishing AD from clinically-established 
FTLD (validated by two years of follow-up) [15]. Furthermore, a study with confirmed FTLD 
patients reported high sensitivity (79%) and specificity (97%) for the Tau/Aβ42 ratio in 
distinguishing FTLD from AD [11]. In the latter study, combining neuropsychological 
measures with CSF biomarkers did not improve the ability to distinguish FTLD from AD, but 
no analyses were performed on the different variants of FTLD.  
Semantic dementia is a rare cause of FTLD [31]. Memory complaints and forgetfulness 
of words, mimicking early AD, are frequent reasons for consultation. Semantic dementia is 
frequently misdiagnosed as AD [18] because the speech in SD is fluent and not easily 
suggestive of progressive aphasia and also because semantic verbal deficits can disturb 
performance in tests of verbal episodic memory. Semantic dementia has different 
histopathological characteristics from AD [19, 21]. In pathologically-confirmed SD patients, 
FTLD with ubiquitin-positive, tau-negative inclusions and TAR-DNA-binding protein 43 
(TDP-43) -positive inclusions were the most common finding [19, 21]. Surprisingly, a 
previous study of CSF biomarkers on SD (n=13 patients without autopsy) was not consistent 
with neuropathological data, showing similar CSF profiles to the AD group [14]. In our 
cohort, SD CSF profiles clearly differed from those of AD. The best biomarker pattern for 
discriminating SD from AD was the P-Tau/Aβ42 ratio, which had high sensitivity (98.3%) 
and specificity (84.2%). The P-Tau/Aβ42 ratio appears to be able to differentiate the 
histopathological lesions associated with AD from those associated with FTD and SD.  
The P-Tau/Aβ42 ratio did not reach a similar power for discriminating AD from 
PNFLA and PCA, lacking sensitivity and specificity. This finding may be attributable to PPA 
not being a clinical entity with a homogeneous pathological profile, but corresponds to three 
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possible phenotypes: SD, progressive non-fluent aphasia (PNFA) and logopenic aphasia 
(see [20] for review). In an autopsy series, tau pathology was the main pathological diagnosis 
in PPA with speech apraxia [36, 37], classically called PNFA [20], while AD was the 
commonest cause of logopenic aphasia, which is characterized by non-fluent speech 
mimicking conduction aphasia [37]. These distinct clinical non-fluent PPA variants were also 
observed in an in-vivo study [22] that used positron tomography emission with the [11C]-
Pittsburgh compound B, a radioligand that was designed to measure the amount of fibrillar 
Aβ deposits [38] and that has been confirmed by a postmortem study in AD [39]. Our data, 
showing an overlap between CSF biomarkers levels between PNFLA and AD (see Figure 2), 
are in agreement with these neuropathological and PET studies. 
Similarly, CSF P-Tau/Aβ42 ratio does not discriminate PCA from AD with the same 
power that we observed in FTD, SD and FCD. Clinicopathological series found that AD was 
the most frequent cause of PCA, accounting for 80-100% of all cases [18, 35, 40]. An in vivo 
study of amyloid deposition by PET confirmed in a single patient that PCA is associated with 
amyloidosis [41].  
Interestingly, individual data showed abnormal ratios for both T-tau/Aβ42 and P-
Tau/Aβ42 in 61.5% of PNFLA patients and in 60% of PCA patients. A recent 
neuropathological study demonstrated that the combination of low Aβ42 and high T-tau level 
in antemortem CSF predicted the presence of AD-associated pathological changes with high 
accuracy and strongly supported the possibility of AD [42]. The P-tau/Aβ42 ratio exhibited 
the best sensitivity and the highest specificity for patients with a confirmed AD diagnosis. 
Consistent with these data, patients with atypical cortical presentation of AD, such as PNFLA 
and PCA, could be identified by CSF biomarkers, particularly T-tau/Aβ42 and P-Tau/Aβ42 
ratios. 
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Combining CSF biomarkers may improve the in-vivo differential diagnosis between AD 
and both FTD and SD, which have distinct neuropathological causes. The combination of 
CSF biomarkers may also help to predict the underlying pathology in focal cortical 
presentations of AD (as in logopenic PPA and PCA) and to identify candidate patients for 
emerging therapies against amyloidosis.  
While pathological data may be important for establishing diagnosis for the different 
groups of patients, no autopsy was available in our cohort. Future studies with autopsy-
confirmed diagnoses are needed to confirm our findings, especially on the PNFLA group. It 
would also be of value to study the biomarker profile in a series of patients that were 
evaluated with positron tomography emission with the PIB, in order to test the concordance 
between CSF biomarkers and PIB data. It should be noted, however, that clinical diagnosis 
was established using accepted consensus criteria; all patients were extensively evaluated with 
clinical, biological, neuropsychological and neuroimaging exams. Furthermore, all patients 
had at least 18 months of clinical follow-up in centers with expertise in the field of dementias. 
Finally, all CSF data were obtained from the same center, except for four patients with SD, 
thus decreasing the risk of potential sources of bias in the biological results. 
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Table 1: Demographic and CSF data of studied groups. 
 
 AD FTD SD FCD PCA PNFLA 
N  60 27 19 17 15 26 
Age 63.6 (57-72) 66 (59-73) 60 (57-68) 56 (52-58) b 62 (57-67) 65.5 (62-71) 
Sex ratio  (M/F) 30/30 15/12 9/10 12/9 3/12 10/16 
Disease duration (years) 3 (2-4) 3 (2-5) 4 (2-7) Not applicated 3 (2-5) 4  (3-5) 
MMSE 20 (17-24) 21 (18-23) 22 (21-27) c 27 (26-28) a d 19 (16-22) 21 (20-24) 
FAB 13 (11-14) 13 (6-14) 15 (12-17) 15 (13-17) a 9 (6-14) 14 (10-17) 
Aβ42 (ng/ml) 237.6 (155.5-315.5) 394 (306.2-473) a 532 (308.2-682.2) a 500 (417-614.5) a d 241 (227.2-382.7) NS d 263.5 (206-351) NS d 
T-tau (ng/ml) 571 (419-796.5) 239 (137-407.4) a 317 (209.5-433.7) a 185 (141.2-262.7) a 436 (368.3-496.5) NS d 414 (288-556) b d 
P-tau (ng/ml) 84.2 (69-107.5) 43.5 (32.5-57) a 46.2 (38.4-67.0) a 34 (30.2-56.9) a  58  (47.3-77.7) c d 59.95 (49-86) c d 
T-tau/Aβ42 2.450 (1.688-3.433) 0.582 (0.396-1.055) a 0.492 (0.35-0.928) a 0.335 (0.31-0.51) a d 1.759 (1.13-2.46) c d 1.528  (0.85-2.31) c d 
P-tau/Aβ42 0.43 (0.26-0.48) 0.13 (0.08-0.15) a 0.18 (0.06-0.13) a 0.074(0.066-0.093) a d 0.26  (0.14-0.31) b d 0.30  (0.16-0.39) b d 
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AD = Alzheimer disease 
FTD = behavioral variant of frontotemporal dementia 
FCD = functional cognitive disorders 
SD = semantic dementia 
PCA = posterior cortical atrophy 
PNFLA = progressive non fluent or logopenic aphasia 
MMSE = Mini-Mental State Exam 
FAB = Frontal Assessment Battery 
Data are presented as median (25th-75th percentile) for each variable.  
Comparison between AD patients and other groups was performed using a non-parametric Mann-Whitney U-test with the following annotations: 
NS Non significant vs AD group 
a  p<0.0001 
b  p<0.01 
c  p<0.05 
d p < 0.05 Mann-Whitney U-Test vs. FTD group 
Please access supplemental material on-line (table 4) to find this data presented in mean and standard deviation (SD) values 
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Table 2: Results of ROC analyses for discrimination of AD from other clinical diagnoses. 
 
Values in parentheses indicate 95% confidence interval 
* Significance of discrimination (P value for significant difference in area under the ROC curve = 0.5) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 26
 Cutoff (pg/mL) Sensitivity (%) Specificity (%) AUC p 
AD vs FCD      
Aβ42 395 93.3 82.4 0.940 (0.862 to 0.981) 0.0001 
T-Tau 289 90 94.1 0.931 (0.849 to 0.976) 0.0001 
P-Tau 64 83.3 94.1 0.900 (0.811 to 0.957) 0.0001 
Tau/Aβ42 0.77 98.3 100 0.988 (0.930 – 1.00) 0.0001 
P-Tau/Aβ42 0.140 98.3 100 0.984 (0.925 – 0.99) 0.0001 
AD vs FTD      
Aβ42 292.1 68.3 85.2 0.817 (0.720 -0.892) 0.0001 
T-Tau 458 70 88.9 0.832 (0.736 - 0.903) 0.0001 
P-Tau 62.5 83.3 85.2 0.851 (0.759 - 0.918) 0.0001 
Tau/Aβ42 1.23 95 85.2 0.926 (0.849 - 0.971) 0.0001 
P-Tau/Aβ42 0.211 91.7 92.6 0.942 (0.871 - 0.981) 0.0001 
AD vs SD      
Aβ42 425 98.3 68.4 0.810 (0.706 - 0.889) 0.0001 
T-Tau 493 65 89.5 0.813 (0.709 - 0.892) 0.0001 
P-Tau 74 63.3 94.7 0.825 (0.723 - 0.901) 0.0001 
Tau/Aβ42 1.05 95 84.2 0.876 (0.783 - 0.940) 0.0001 
P-Tau/Aβ42 0.143 98.3 84.2 0.864 (0.768 - 0.931) 0.0001 
AD vs PNFLA      
Aβ42 234 50 69.2 0.581 (0.470 - 0.687) 0.2346 
T-Tau 616 46.7 88.5 0.686 (0.576 - 0.781) 0.0017 
P-Tau 62 85 53.8 0.671 (0.562 - 0.769) 0.0044 
Tau/Aβ42 1.678 75 65.4 0.713 (0.606 - 0.806) 0.0002 
P-Tau/Aβ42 0.296 68.3 69.2 0.688 (0.579 - 0.783) 0.0014 
AD vs PCA      
 27
Aβ42 221 41.7 86.7 0.614 (0.494 - 0.724) 0.1796 
T-Tau 497 63.3 80 0.663 (0.545 - 0.768) 0.0251 
P-Tau 59.5 86.7 60 0.705 (0.588 - 0.805) 0.0027 
Tau/Aβ42 1.33 88.3 46.7 0.706 (0.589 - 0.805) 0.0026 
P-Tau/Aβ42 0.311 61.7 80 0.733 (0.618 - 0.828) 0.0003 
AD vs SD + FTD      
Aβ42 379 91.7 60.9 0.814 (0.727 - 0.883) 0.0001 
T-Tau 465 68.3 87 0.824 (0.738 - 0.891) 0.0001 
P-Tau 64 83.3 80.4 0.840 (0.757 - 0.904) 0.0001 
Tau/Aβ42 1.23 95 84.8 0.905 (0.833 - 0.954) 0.0001 
P-Tau/Aβ42 0.211 91.7 89.1 0.911 (0.839 - 0.957) 0.0001 
AD vs SD + FTD + FCD      
Aβ42 379 91.7 66.7 0.848 (0.772 - 0.906) 0.0001 
T-Tau 341 88.3 73 0.853 (0.778 - 0.910) 0.0001 
P-Tau 64 83.3 84.1 0.857 (0.782 - 0.913) 0.0001 
Tau/Aβ42 1.23 95 88.9 0.928 (0.866 - 0.966) 0.0001 
P-Tau/Aβ42 0.211 91.7 92.1 0.930 (0.870 - 0.968) 0.0001 
 
 
 
 
 
 
 
 28
Table 3: Number of patients (%) with altered values of individual CSF biomarkers and their ratios, with patients divided into the studied groups. 
The employed cut-offs were those found from ROC curves for discriminating AD from FTD pooled with SD. 
 
 
 AD FCD FTD SD PCA PNFLA 
Aβ42 < 379 pg/ml 55/60 (91.6) 3/17 (17.64) 12/27 (44) 6/19 (31.5) 11/15 (73) 21/26 (80.7) 
T-tau > 465 pg/ml 41/60 (68.3) 2/17 (11.76) 3/27 (11.1) 4/19 (21.05) 6/15 (40) 10/26 (38.46) 
P-Tau > 64.3 pg/ml 50/60 (83.3) 1/17 (5.88) 4/27 (14.81) 5/19 (26) 6/15 (40) 12/26 (46.1) 
T-tau/Aβ42 > 1.23 57/60 (95) 0/17 4/27 (14.81) 3/19 (15.8) 11/15 (73) 17/26 (65.3) 
P-tau/Aβ42 > 0.211 54/60 (90) 0/17 2/27 (7.4) 3/19 (15.8) 9/15 (60) 16/26 (61.5) 
T-tau/Aβ42 >1.23 and P-tau/Aβ42 > 0.211 54/60 (90) 0/17 1/27 (3.7) 3/19 (15.8) 9/15 (60) 16/26 (61.5) 
 
 
 
 
 29
Figure 1: ROC curves of the sensitivity and specificity for individual CSF biomarkers and 
ratios in discriminating AD patients from PCA (A), FTD (B), SD (C) and PNFLA (D) 
patients. The combination of the two ratios (T-tau/Aβ42>1.23 and P-tau/Aβ42 > 0.211) 
discriminated AD patients from PCA (A), FTD (B) , SD (C) and PNFLA (D) patients with 
95% sensitivity and 94% specificity, with a positive predictive value of 93% and a negative 
predictive value of 95.4%. 
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Figure 2: Scatterplot of CSF P-tau/Aβ42 ratio in patients according to clinical diagnosis. 
Figure 2a shows distinct distribution of these scores between AD patients and FTD, SD and 
FCD patients. Figure 2b shows greater overlap in the distribution of P-tau/Aβ42 ratio in AD, 
PNFLA and PCA patients. 
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Appendices: Supplemental material on-line 
 
Table 4: Demographic and CSF data of studied groups. Data are presented as mean (± SD, maximum - minimum) for each variable.  
. 
AD = Alzheimer disease 
FTD = behavioral variant of frontotemporal dementia 
FCD = functional cognitive disorders 
SD = semantic dementia 
PCA = posterior cortical atrophy 
PNFLA = progressive non fluent or logopenic aphasia 
MMSE = Mini-Mental State Exam 
FAB = Frontal Assessment Battery 
Comparison between AD patients and other groups was performed using a non-parametric Mann-Whitney U-test with the following annotations: 
NS Non significant 
a  p<0.0001 
b  p<0.01 
c  p<0.05 
d p < 0.05 Mann-Whitney U-Test vs. FTD group 
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 AD FTD SD FCD PCA PNFLA 
 
N 60   27 19 17 15 26 
Age  64.3 ± 9.8 
(48  – 85) 
63.11 ± 11.2 
(24  –  86) 
61.41 ± 7.45 
(50 – 76) 
57 ± 10 b d 
(44 – 85) 
71 ± 5.66 
(67 – 75) 
66 ± 7.45 
(46 – 82) 
Sex ratio M/F  29 M / 32 F 13 M / 14 F 9 M/ 8 F 12 M / 9 F 3 M / 12 F 12 M / 14 F 
Disease duration 
(years) 
4 ± 2.48 
(1 – 14) 
4.22 ± 3.33 
(1 – 14) 
4.27  ± 3.21 
(1 – 11) 
Not applicated 3.42 ± 1.87 
(2 – 8) 
4 ± 2.39 
(1 – 10) 
MMSE 20 ± 5.41 
(6 – 29) 
20 ± 4.62 
(10 – 27) 
22 ± 6 c 
(7 – 30) 
27 ± 1.94 a d 
(24 – 30) 
19 ± 5.19 
(6 – 26) 
22 ± 4.27 
(13 – 30) 
FAB 11 ± 3.84 
(0 – 17) 
10 ± 4.72 
(1 – 15) 
13.5 ± 2.77 
(10 – 17) 
15 ± 2.7 a 
(9 –18) 
9.14 ± 4.47 
(0 – 16) 
13 ± 3.81 
(6 – 18) 
Aβ42 244.23 ± 95.31 
(62 – 460) 
408.36 ± 149.80 a 
(187 – 817) 
563.94 ± 404.73 b 
(62 – 1711) 
530.7 ± 168.96 a d 
(286 – 900) 
288.42 ± 99.49 NS d 
(129 – 456) 
315.44 ± 174.27 NS d 
(120 – 786) 
T-tau 554 ± 306.85 
 (131 – 1763) 
312 ± 217.72  a 
 (84 – 906) 
354.47 ± 256.56 b 
(74 – 1190) 
207.65 ± 107.67 a 
(70 – 529) 
502.36 ± 243.0 NS d 
(168 – 1110) 
477 ± 317.93 c d 
(127 – 1300) 
P-tau 84 ± 38.69 
(15 – 212) 
48.4 ± 22.92 a 
(12 – 106) 
54.28 ± 34.40 a 
 (12 – 163) 
41.67 ± 18.62 a d 
 (17 – 83) 
68.15 ± 33.48 c d 
(27 – 143) 
73 ± 39.45 c d 
(34 – 178) 
T-tau/Aβ42 2.41 ± 1.67 
 (0.31 – 8.59) 
0.582 ± 0.72 a 
(0.25 – 3.69) 
1.12 ± 1.47 a 
(0.26 – 5.5) 
0.39 ± 0.15 a d 
 (0.13 – 0.77) 
1.92 ± 1.12 c d 
(0.69 – 4.99) 
1.84 ± 1.35 b d 
(0.23 – 5.83) 
P-Tau/Aβ42 0.362 ± 0.22 
 (0.035 – 1.255) 
0.10 ± 0.09 a 
(0.04 – 0.51) 
0.18 ± 0.26 a 
(0.03 – 1.03) 
0.08 ± 0.027 a 
(0.03 – 0.14) 
0.26 ± 0.15 b d 
(0.05 – 0.64) 
0.29 ± 0.20 b d 
(0.04 – 0.86) 
 


